Theravance Biopharma, Inc. (TBPH)

Theravance Biopharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	219.77	167.81	37.8	39.55	298.17	89.96
Short-Term Investments	167.89	147.55	50.55	62.88	29.31	83.51
Cash & Short-Term Investments	387.66	315.36	88.35	102.43	327.48	173.47
Cash Growth	14.42%	256.94%	-13.74%	-68.72%	88.79%	-40.78%
Accounts Receivable	20.38	45.54	18.44	17.47	16.79	14.07
Other Receivables	-	50	50	-	-	-
Receivables	20.38	95.54	68.44	17.47	16.79	14.07
Prepaid Expenses	8.62	7.56	4.28	13.64	9.2	18.81
Other Current Assets	-	-	-	-	-	43.53
Total Current Assets	416.66	418.46	161.07	133.54	353.46	249.87
Property, Plant & Equipment	27.1	30.27	35.77	45.36	52	53.35
Long-Term Investments	-	11.13	-	-	-	-
Other Long-Term Assets	26.01	25.72	157.32	203.1	201.94	71.6
Total Assets	469.77	485.57	354.16	382	607.4	374.82

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	0.65	2.57	2.24	1.52	1.55	3.1
Accrued Expenses	19.32	19.5	13.28	12.83	20.41	37.95
Current Portion of Long-Term Debt	-	-	-	-	-	16.94
Current Portion of Leases	10.8	10.95	10.71	3.92	6.75	0.5
Current Income Taxes Payable	-	5.29	5.85	-	-	-
Current Unearned Revenue	-	-	-	-	-	0.1
Other Current Liabilities	-	-	-	6.49	-	-
Total Current Liabilities	30.77	38.3	32.09	24.77	28.72	58.59
Long-Term Debt	-	-	-	-	-	599.39
Long-Term Leases	27.77	31.76	39.11	45.24	45.41	52.68
Long-Term Unearned Revenue	-	-	-	-	0.19	0.31
Other Long-Term Liabilities	121.53	118.79	107.42	99	91.29	2.42
Total Liabilities	180.07	188.85	178.62	169	165.6	713.39

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	0	0	-	-	0	0
Additional Paid-In Capital	1,160	1,156	1,141	1,122	1,296	1,387
Retained Earnings	-870.46	-859.63	-965.52	-909.1	-853.91	-1,726
Comprehensive Income & Other	-0.08	0.06	0.01	-0.07	-0.02	-
Shareholders' Equity	289.71	296.72	175.55	213	441.8	-338.57
Total Liabilities & Equity	469.77	485.57	354.16	382	607.4	374.82

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	38.57	42.7	49.82	49.16	52.16	669.52
Net Cash (Debt)	349.09	283.78	38.53	53.27	275.32	-496.05
Net Cash Growth	19.41%	636.52%	-27.67%	-80.65%	-	-
Net Cash Per Share	6.73	5.51	0.79	0.96	3.74	-7.14
Filing Date Shares Outstanding	51.92	51.49	49.47	48.16	62.86	74.7
Total Common Shares Outstanding	51.89	51.07	49.47	48.09	65.23	74.44
Working Capital	385.9	380.16	128.98	108.77	324.75	191.28
Book Value Per Share	5.58	5.81	3.55	4.43	6.77	-4.55
Tangible Book Value	289.71	296.72	175.55	213	441.8	-338.57
Tangible Book Value Per Share	5.58	5.81	3.55	4.43	6.77	-4.55
Machinery	-	3.67	3.74	3.68	19.04	26.03
Leasehold Improvements	-	25.28	25.32	26.21	24.58	24.05

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: Aug 10, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 26, 2026

Data Sources Report a data error